Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of idiopathic pulmonary fibrosis (IPF).
| Condition | Intervention | Phase |
|---|---|---|
|
Idiopathic Pulmonary Fibrosis Lung Disease Pulmonary Fibrosis |
Drug: Imatinib Mesylate (Gleevec) |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Educational/Counseling/Training |
| Official Title: | A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary Fibrosis |
- Progression defined as a greater than 10% decline in the forced vital capacity (FVC) or death
- Change from baseline in % predicted diffusing capacity of the lung for carbon monoxide (DLCO) at 96 weeks
- Change from baseline in the resting arterial blood gas (ABG) assessment of A-a gradient at 96 weeks
- Change in the number of meters walked in the 6 minute walk test at 96 weeks
- Change from baseline in high-resolution computed tomography (HRCT) at 96 weeks
- Change from baseline in the quality of life (QOL) assessments
- Change in the modified C-reactive protein (CRP) score at 96 weeks
- Mortality at 96 weeks
| Estimated Enrollment: | 120 |
| Study Start Date: | April 2003 |
| Estimated Study Completion Date: | August 2007 |
This is a multicenter, double-blind, parallel, placebo-controlled, randomized phase 2 study to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of Idiopathic Pulmonary Fibrosis (IPF). One-hundred- twenty patients will be enrolled in the trial in total. Subjects must have a diagnosis made by HRCT showing definite or probable IPF and clinical symptoms consistent with IPF with onset between 3 and 36 months prior to screening. Subjects will be randomly assigned to receive either Gleevec 600 mg orally or placebo, once per day for approximately 2 years. The primary efficacy will be progression defined as a greater than 10% decline in the forced vital capacity or death. Measures of safety will include all randomized patients who receive at least one dose of study medication. All adverse events and serious adverse events will be separately tabulated and mapped to a standard classification system and grouped by body system. Any serious adverse events that occur during the trial and 30 days after the end of therapy will be reported to the FDA within 24 hours and followed to outcome.
Eligibility| Ages Eligible for Study: | 20 Years to 79 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical symptoms consistent with IPF with onset between 3 months and 36 months prior to screening
Worsening as demonstrated by any one of the following within the past year:
- >10% decrease in FVC % of predicted,
- Worsening chest x-ray or
- Worsening dyspnea at rest or on exertion
- Age 20 –79 years of age. Subjects aged 20-50 must have diagnosis by either open or video-assisted thoracic surgery (VATS) lung biopsy
Diagnosis must be made by (HRCT) showing definite or probable IPF AND either of the following:
- Open or VATS lung biopsy showing definite or probable usual interstitial pneumonitis (UIP)
- Non-diagnostic transbronchial biopsy to exclude other conditions (including granulomatous disease and malignancies) AND abnormal pulmonary function tests (reduced FVC or decreased DLCO or impaired gas exchange with rest or exercise) AND 2 of the following:
- Age >50 years
- Insidious onset of otherwise unexplained dyspnea or exertion
- Bibasilar, inspiratory crackles on examination
- FVC> 55% of predicted value at baseline
- DLCO > 35% of predicted value at screening
- PaO2 >60 mmHg (sea level) or 55 mmHg (altitude) at rest on room air
- Able to understand and willing to provide informed consent prior to any study procedures
Exclusion Criteria:
- History of clinically significant environmental exposure known to cause pulmonary fibrosis
- Diagnosis of connective tissue disease
- FEV1/FVC ratio < 0.6 at screening (post-bronchodilator)
- Residual volume > 120% predicted at screening
- Evidence of active infection
- Any condition other than IPF, which, in the opinion of the site principal investigator, is likely to result in the death of the patient within the next year
- History of unstable or deteriorating cardiac or neurologic disease
- Women with child bearing potential
- Current treatment with corticosteroids, cytoxan, azathioprine, colchicines, pirfenidone, interferon gamma or beta, anti-tumor necrosis factor therapy or with endothelin receptor blockers.
Contacts and Locations More Information
Additional Information:
No publications provided by Daniels, Craig E., M.D.
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00131274 History of Changes |
| Other Study ID Numbers: | CST1571E2401 |
| Study First Received: | August 17, 2005 |
| Last Updated: | October 4, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Daniels, Craig E., M.D.:
|
Pulmonary Fibrosis Respiratory Diseases Interstitial Lung Disease Usual Interstitial Pneumonia |
Additional relevant MeSH terms:
|
Fibrosis Lung Diseases Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Pathologic Processes Respiratory Tract Diseases Idiopathic Interstitial Pneumonias Lung Diseases, Interstitial |
Imatinib Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 22, 2013